$82.26 0.7 0.9%
Last Trade - 05/06/20
| Market Cap | £163.97bn |
| Enterprise Value | £180.28bn |
| Revenue | £37.97bn |
| Position in Universe | 32nd / 6325 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. Vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices.
| Last Annual | December 31st, 2019 |
| Last Interim | March 31st, 2020 |
| Incorporated | July 28, 1970 |
| Public Since | June 15, 1946 |
| No. of Shareholders: | 109,500 |
| No. of Employees: | 71,000 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | Dow Jones Composite , Dow Jones Industrial Average , FTSE Global 100, S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | New York Stock Exchange |
| Shares in Issue | 2,524,101,191 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 2000 Galloping Hill Rd, KENILWORTH, 07033-1310, United States |
| Web | http://www.merck.com/ |
| Phone | +1 908 7404000 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
As of 05/06/20, shares in Merck & Co Inc are trading at $82.26, giving the company a market capitalisation of £163.97bn. This share price information is delayed by 15 minutes.
Shares in Merck & Co Inc are currently trading at $82.26 and the price has moved by 1.01% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Merck & Co Inc price has moved by -6.75% over the past year.
Of the analysts with advisory recommendations for Merck & Co Inc, there are there are currently 6 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Merck & Co Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Merck & Co Inc is scheduled to issue upcoming financial results on the following dates:
The Merck & Co Inc dividend yield is 2.82% based on the trailing twelve month period.
Last year, Merck & Co Inc paid a total dividend of 2.32, and it currently has a trailing dividend yield of 2.82%. Looking ahead, shares in Merck & Co Inc are due to go ex-dividend on 2020-06-12 and the next dividend pay date is 2020-07-07.
Merck & Co Inc are due to go ex-dividend on 2020-06-12 and the next dividend pay date is 2020-07-07. The historic dividend yield on Merck & Co Inc shares is currently 2.82%.
To buy shares in Merck & Co Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Merck & Co Inc are currently trading at $82.26, giving the company a market capitalisation of £163.97bn.
Here are the trading details for Merck & Co Inc:
Based on an overall assessment of its quality, value and momentum, Merck & Co Inc is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Merck & Co Inc are currently priced at $82.26. At that level they are trading at 7.06% discount to the analyst consensus target price of 0.00.
Analysts covering Merck & Co Inc currently have a consensus Earnings Per Share (EPS) forecast of 5.315 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Merck & Co Inc. Over the past six months, the relative strength of its shares against the market has been -6.71%. At the current price of $82.26, shares in Merck & Co Inc are trading at -1.11% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Merck & Co Inc PE ratio based on its reported earnings over the past 12 months is 15.1. The shares are currently trading at $82.26.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Merck & Co Inc's management team is headed by:
Here are the top five shareholders of Merck & Co Inc based on the size of their shareholding:
